Global Antimicrobial resistance Platform for ONE Burden Estimates
Environment
Surveillance
- Luigia Scudeller, IRCCS Fondazione Policlinico San Matteo, Italy (Coordinator)
- Gabriel Levy Hara, Universidad Maimónides, Argentina (Observer)
- Marc Mendelson, University of Cape Town, South Africa (Observer)
- Souha Kanj, American University of Beirut Medical Center, Lebanon (Observer)
- Herman Goossens, University of Antwerp, Belgium (Observer)
- Ramanan Laxminarayan, Center for Disease Dynamics, Economics & Policy, India (Observer)
- Finola Leonard, University College Dublin, Ireland (Observer)
- Malgorzata Karolina Mikulska, IRCCS Ospedale Policlinico San Martino, Italy (Observer)
- Bruno González Zorn, Universidad Complutense de Madrid, Spain (Observer)
- Christine Årdal, Norwegian Institute of Public health, Norway (Observer)
- Esabiha Essack, University of KwaZulu-Natal, South Africa (Observer)
- Evelina Tacconelli, University Hospital Tübingen, Germany (Observer)
- Alessandra Bandera, IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation, Italy (Observer)
- Marc Bonten, Julius Center Research Program Infectious Diseases, Netherlands (Observer)
- Jesús Rodríguez-Baño, Hospital Universitario Virgen Macarena, Spain (Observer)
- Stephan Harbarth, University Hospitals Geneva, Switzerland (Observer)
- Peter Jørgensen Søgaard, Royal Swedish Academy of Sciences, Sweden (Observer)
- Marlieke De Kraker, University Hospitals Geneva, Switzerland (Observer)
- Kevin Outterson, CARB-X, Boston University, USA (Observer)
- Luca Guardabassi, University of Copenhagen, Denmark (Observer)
How much does antimicrobial resistance cost? The overall worldwide cost attributable to it is certainly high, but remains largely unknown. The economic studies performed so far only consider direct costs associated with human infection from a hospital perspective, primarily from high-income countries. But antimicrobial resistance is a One Health issue: it applies to human, animal, and environmental health. We have developed a framework, called The Global Antimicrobial Resistance Platform for ONE-Burden Estimates (GAP-ON€), that shows the immense number of often hidden, human, animal and environmental costs across the many individual and societal dimensions, inextricably linked together in a One Health picture. There are many bacteria (but other germs as well) that can colonize or even cause disease in human beings and animals, in a common environment. These cause direct health costs (costs of medicines, hospital stay, diagnostic tests, etc) and also indirect costs (loss of working days, loss of farm animals in the food chain, insurance costs etc) Building on this framework, future studies will be able to assess more precisely what the costs of antimicrobial resistance are, and will hopefully increase global public awareness of the real burden of AMR in all areas of life, across the world.
